Molecular Biology of B Cells

3rd Auflage
ISBN: 978-0-323-95895-0
Verlag: Elsevier Science

Buch, Englisch, 548 Seiten, Format (B × H): 216 mm x 276 mm, Gewicht: 1000 g

Molecular Biology of B Cells, Third Edition provides a comprehensive reference on how B cells are generated, selected, activated, and engaged in antibody production. These developmental and stimulatory processes are described in molecular, immunological, and genetic terms to give a clear understanding of complex phenotypes. The book offers an integrated view of B cells to produce a normal immune response as a constant, and the molecular basis of numerous diseases due to B cell abnormality. This new edition provides updated research on B cell development and function, the use of therapeutic antibodies in cancer and infectious disease, and more. With updated research and continued comprehensive coverage of all aspects of B cell biology, Molecular Biology of B Cells, this updated release is a definitive resource, vital for researchers across molecular biology, immunology, and genetics.

Autoren/Hrsg.

Honjo, Tasuku

Reth, Michael

Radbruch, Andreas

Alt, Frederick

Martin, Alberto

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien
• Naturwissenschaften Biowissenschaften Biochemische Immunologie

Inhaltsverzeichnis

1. The Structure and Regulation of the Immunoglobulin Loci
Joseph S. Lucas, Cornelis Murre, Ann J. Feeney and Roy Riblet
2. The Mechanism, Regulation and Evolution of V(D)J Recombination
David G. Schatz, Yiwen Zhang, Jianxiong Xiao, Shan Zha, Yu Zhang and Frederick W. Alt
3. The Origin of V(D)J Diversification
Ellen Hsu and Susanna M. Lewis
4. The Variable Lymphocyte Receptor B System of the Jawless Vertebrates
Thomas Boehm, Max D. Cooper, Masayuki Hirano, Sabyasachi Das, Ryo Morimoto and Jonathan P. Rast
5. Structure and Signalling Function of the B-Cell Antigen Receptor and Its Coreceptors
Michael Reth, Kathrin Klasener, Lars Nitschke and Michael R. Gold
6. Fc Receptors
Jeffrey V. Ravetch and Stylianos Bournazos
7. Transcriptional Regulation of Early B-Cell Development
Ashley P. Ng, Rhiannon Morris and Stephen L. Nutt
8. Relationship between B-Cell Populations, Development and Function of B-Cell Subsets
Eva Piano Mortari and Rita Carsetti
9. B-Cell Development to Immunity and Tolerance
Fritz Melchers, Mir-Farzin Mashreghi and Peter K. Jani
10. The Role of the BAFF and Lymphotoxin Pathways in B Cell Biology
Fabienne Mackay and Jennifer L. Gommerman
11. Mechanism and Regulation of Immunoglobulin Class Switch Recombination
Fei-Long Meng, Lekha Nair, Keith C. Fernandez, Uttiya Basu and Jayanta Chaudhuri
12. Somatic Hypermutation
Jana Ridani, Philip Barbulescu, Alberto Martin and Javier M. Di Noia
13. Molecular Mechanism of Activation-Induced Cytidine Deaminase
Nasim A. Begum, Maki Kobayashi, Hitoshi Nagaoka and Tasuku Honjo
14. Molecular Pathogenesis of B-Cell Lymphomas
Laura Pasqualucci, Pantaleo De Simone and Riccardo Dalla-Favera
15. Human Immunodeficiencies Caused by Inborn Errors of B-Cell Development or Function
Stuart G. Tangye, Jean-Laurent Casanova and Cindy S. Ma
16. Memory B Cells and Plasma Cells
Mairi Anne McGrath, Florian Weisel, Andreas Radbruch and Mark Shlomchik
17. Homoeostatic Versus Pathogenic Autoantibodies: Origin, Structure and Effector Functions
Yemil Atisha-Fregoso, Rita Pozovskiy, Shabirul Haque, Manami Watanabe, Yong-Rui Zou and Betty Diamond
18. Anti-Tumour Necrosis Factor and New Paradigms for Therapies Using Antibodies
Sergei A. Nedospasov, Marina S. Drutskaya and Andrey A. Kruglov
19. Therapeutic Targeting of B Cells and Plasma Cells with a Focus on Multiple Sclerosis and Other Autoimmune Conditions
Andreia C. Lino and Thomas Dorner
20. IMGT Immunoglobulin Repertoire
Analysis and Antibody Humanization Marie-Paule Lefranc
21. Mucosal Immunity to Bacteria and Immunoglobulin A Synthesis
Andrew J. Macpherson, Tim Rollenkse, Lucia M. Kato and Sidonia Fagarasan
22. B-Cell Metabolism
Julia Jellusova

Über Autor(innen)

Radbruch, Andreas
Andreas Radbruch did his PhD at the Genetics Institute of the Cologne University, Germany, with Klaus Rajewsky. He later became Associate Professor there and was a visiting scientist with Max Cooper and John Kearney at the University of Alabama, Birmingham. In 1996, he became Director of the German Rheumatism Research Centre Berlin, a Leibniz Institute, and in 1998, Professor of Rheumatology at the Charité, the Medical Faculty of the Humboldt University of Berlin.

A biologist by education, Andreas Radbruch early on worked on somatic variants in myeloma and hybridoma cells lines, modeling antibody class switching and somatic hypermutation. In this context, his lab originally developed the MACS technology. Andreas Radbruch then showed that recombination is the physiological mechanism of class switching in vivo, in plasmablasts isolated ex vivo. Moreover, he could show that in vivo, class switch recombination is targeted to the same Ig class on both IgH loci of a cell, reflecting a tight control of targeting of recombination. An essential element of this control is transcription of recombinogenic sequences, and the processing of these switch (germline) transcripts, as became evident from targeted deletion of the control regions involved. The switch transcripts are induced by cytokines of T helper cells, e.g. interleukin-4. The Radbruch lab contributed essentially to our current understanding of the polarization and imprinting of T helper cells expressing interleukin-4 (Th2) versus those expressing interferon-? (Th1).

The lab then addressed the organization of immunological memory as such. First they identified longlived (memory) plasma cells, mostly residing in bone marrow but also in secondary lymphoid organs and in inflamed tissues. They could show that these cells individually persist in dedicated survival niches, organized by CXCL12-expressing mesenchymal stroma cells. They identified different, dedicated niches for CD4+ and CD8+ memory T cells in the bone marrow, too, and could show that, at least in immune responses to vaccines, memory T cells are mostly maintained in bone marrow, resting in terms of proliferation and gene expression. Thus memory niches organize and maintain memory, and bone provides a privileged environment for resting memory cells. In chronic antibody-mediated diseases, Andreas Radbruch´s lab identified pathogenic antibody-secreting memory plasma cells as critical mediators of chronicity, refractory to conventional immunosuppression, and thus representing a novel therapeutic target. Similarly, in chronic T cell-mediated diseases, the pathogenic T cells induce and adapt to chronicity. Recently, the Radbruch group has identified Twist1, HopX and the microRNAs miR-182 and miR148a as molecular adaptations of proinflammatory T cells to chronicity, and innovative therapeutic targets.

Andreas Radbruch´s work has been recognized by the Carol Nachman Prize for Rheumatology (2011), an Advanced Grant of the European Research Council (ERC, 2010), the Federal Cross of Merit (2008) and the Aronson Award (2000). He is a member of the Berlin-Brandenburg Academy of Sciences and Humanities (BBAW), the European Molecular Biology Organization (EMBO) and the German National Academy of Sciences Leopoldina.

Honjo, Tasuku
Dr. Tasuku Honjo graduated from Kyoto University Faculty of Medicine in 1966 (M.D.). After obtaining his Ph.D. in Biochimistry (Dr. O. Hayaishi), he spent 4 years in the U.S.A. as a postdoctoral fellow first in Carnegie Institution of Washington (Dr. D. Brown), and then in NIH (Dr. P. Leder) where he initiated studies on immunoglobulin genes. He returned to Tokyo University as an assistant professor in 1974, and then moved to Osaka University School of Medicine as Professor of Genetics in 1979. He succeeded to Dr. O. Hayaishi after his retirement at the Department of Medical Chemistry in Kyoto University. He also served as Dean of Medical School (1996-2000 and 2004-2005), and Executive Member of Council for Science and Technology Policy, Cabinet Office (2006-2012). Currently, he is Professor of Department of Immunology and Genomic Medicine, Kyoto University, and also Chairman of Board of Directors, Shizuoka Prefectural University Corporation.

Dr. Honjo is well known for his discovery of activation-induced cytidine deaminase that is essential for class switch recombination and somatic hypermutation. He has established the basic conceptual framework of class switch recombination starting from discovery of DNA deletion (1978) and S regions (1980), followed by elucidation of the whole mouse immunoglobulin heavy-chain locus. His contribution further extended to cDNA cloning of IL-4 and IL-5 cytokines involved in class switching and IL-2 receptor alpha chain. Aside from class switching recombination, he discovered PD-1 (program cell death 1), a negative coreceptor at the effector phase of immune response and showed that PD-1 modulation contributes to treatments of viral infection, tumor and autoimmunity. In addition, he is known to be a discoverer of RBP-J, a nuclear protein that interacts with the intracellular domain of Notch in the nucleus. Notch/RBP-J signaling has been shown to regulate a variety of cell lineage commitment including T and B cells.

For these contributions, Dr. Honjo has received many awards, including the Noguchi Hideyo Memorial Prize for Medicine (1981), Imperial Prize, Japan Academy Prize (1996), Robert Koch Prize (2012), and Order of Culture (2013). He is an honorary member of the American Association of Immunologists. He has been honored by the Japanese Government as a person of cultural merits (2000). He has also been elected as a foreign associate of National Academy of Sciences, USA in 2001, as a member of Leopoldina, the German Academy of Natural Scientists in 2003, and as a member of Japan Academy in 2005.

Alt, Frederick
Frederick W. Alt is a Howard Hughes Medical Institute (HHMI) Investigator and Director of the Program in Cellular and Molecular Medicine (PCMM) at Boston Children's Hospital (BCH). He is the Charles A. Janeway Professor of Pediatrics and Professor of Genetics at Harvard Medical School. He works on elucidating mechanisms that generate antigen receptor diversity and, more generally, on mechanisms that generate and suppress genomic instability in mammalian cells, with a focus on the immune and nervous systems. Recently, his group has developed senstive genome-wide approaches to identify mechanisms of DNA breaks and rearrangements in normal and cancer cells. He has been elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the European Molecular Biology Organization. His awards include the Albert Szent-Gyorgyi Prize for Progress in Cancer Research, the Novartis Prize for Basic Immunology, the Lewis S. Rosensteil Prize for Distinugished work in Biomedical Sciences, the Paul Berg and Arthur Kornberg Lifetime Achievement Award in Biomedical Sciences, and the William Silan Lifetime Achievement Award in Mentoring from Harvard Medical School.

Martin, Alberto
Dr. Alberto Martin received his MSc and PhD from the Department of Immunology at the University of Toronto. He is current a Professor at the same university. He also is the Sanofi Pasteur Chair in Human Immunology. Dr. Martin was a Section editor for the Encyclopedia of Immunobiology (2016) and is the Editor for PLoS Genetics, the Journal of Immunology, Frontiers in B cell Biology, and BMC Immunology. He has received a number of awards including the 2008 Canadian Society for Immunology New Investigator Award, the Top 10 funded research of 2014 from the Canadian Cancer Society, and the 2017 Canadian Society for Immunology Investigator Award.